Imugene: Receives $4.8M tax rebate on cancer research
Clinical-stage immuno-oncology company Imugene (IMU) has received a hefty tax rebate for its research and development (R&D) spending
The company has banked a...
Imugene: Receives FDA approval for PD1-Vaxx trial
Imugene (IMU) has received approval from the U.S. Food and Drug Administration (FDA) to begin a clinical trial for its PD1-Vaxx drug
Then...

